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Abstract
Purpose Malignant pleural mesothelioma (MPM) is a
highly lethal neoplasm. S-1 has been developed as a novel
oral antineoplastic agent based on the modulation of 5-
ﬂuorouracil (5-FU) bioactivity. This study was conducted
to investigate the preclinical therapeutic effect of S-1 on
MPM.
Methods We used three human MPM cell lines, Y-
MESO-14, NCI-H290 and MSTO-211H. In vitro prolifer-
ation of human MPM cells was determined by MTT assay.
Human MPM cells were orthotopically implanted into
thoracic cavity of SCID mice. Tumor-bearing mice were
treated with S-1 or vehicle.
Results The combination of 5-FU and 5-chloro-2,4-di-
hydroxypyridine (CDHP) was more effective than 5-FU
alone in inhibiting MPM cell proliferation in vitro. This
combination was most effective in Y-MESO-14 cells,
which co-expressed high protein level of dihydropyrimi-
dine dehydrogenase (DPD) and thymidine phosphorylase
(TP). In vivo data showed that treatment with S-1 signiﬁ-
cantly reduced thoracic tumors and pleural effusion pro-
duced by Y-MESO-14 cells. Moreover, treatment with S-1
prolonged the survival of Y-MESO-14 cell-bearing SCID
mice.
Conclusions We demonstrated that S-1 was effective for
inhibiting the proliferation of MPM cells, particularly with
both DPD and TP expressions, suggesting that S-1 might
be therapeutically effective for control of MPM.
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Abbreviations
MPM Malignant pleural mesothelioma
5-FU 5-ﬂuorouracil
FT Tegafur
CDHP 5-chloro-2,4-dihydroxypyridine
OXO Potassium oxonate
DPD Dihydropyrimidine dehydrogenase
FUTP 5-ﬂuorouridine-50-triphosphate
TP Thymidine phosphorylase
FBS Fetal bovine serum
HUVEC Human umbilical vein endothelial cells
HPMC Hydroxypropyl methylcellulose
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium
PVDF Polyvinylidene diﬂuoride
PBS Phosphate-buffered saline
FdUMP 5-ﬂuoro-20deoxyuridine-50-monophosphate
Introduction
Malignant pleural mesothelioma (MPM) is a highly
aggressive fatal malignancy which closely related to
T. T. Van   S. Kakiuchi   S. Sato   T. Kuramoto   S. Akiyama  
S. Sone
Department of Medical Oncology, Institute of Health
Biosciences, University of Tokushima Graduate School,
3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan
M. Hanibuchi   H. Goto   A. Mitsuhashi   Y. Nishioka  
S. Sone (&)
Department of Respiratory Medicine and Rheumatology,
Institute of Health Biosciences, University of Tokushima
Graduate School, 3-18-15 Kuramoto-cho,
Tokushima 770-8503, Japan
e-mail: ssone@clin.med.tokushima-u.ac.jp
123
Cancer Chemother Pharmacol (2011) 68:497–504
DOI 10.1007/s00280-010-1503-xprevious exposure to asbestos [1–3]. MPM was once con-
sidered rare, but its incidence is increasing worldwide, with
expected peak before 2020 in Europe [4, 5] or around
2030–2040 in Asia [6, 7].
The management of MPM is still very challenging by
lack of sufﬁcient treatment option. In addition, because of
the delayed manifestation and the insidiously progressive
nature of this disease, the patients at the time of diagnosis
are often older and often have advanced stages. As a result,
chemotherapeutics have become the mainstay approach for
treatment of this disease [8, 9]. Although the multi-targeted
antifolate agent, pemetrexed, in combination with cisplatin,
was recently approved as ﬁrst-line treatment against MPM,
the overall prognosis of patients with MPM still remains
very poor [10, 11]. Therefore, the development and testing
of new antitumor agents for the treatment of MPM are
deﬁnitely pressing.
S-1 is a novel ﬂuoropyrimidine anticancer agent with
dual actions, designed to enhance the anticancer activity
of 5-ﬂuorouracil (5-FU) and reduce its gastrointestinal
toxicity through the deliberate combination of the fol-
lowing components: an oral ﬂuoropyrimidine agent
tegafur (FT) and two enzyme inhibitors 5-chloro-2,4-di-
hydroxypyridine (CDHP) and potassium oxonate (OXO)
in a molar ratio of 1:0.4:1 [12]. CDHP, a pyrimidine
derivative and a reversible competitive inhibitor of
dihydropyrimidine dehydrogenase (DPD), is about 180
times more potent than uracil in inhibiting DPD in both
the tumor and the liver, thus allowing greater concen-
trations of 5-FU to go through the anabolic pathway,
producing the active metabolites [13]. OXO localizes in
the gastrointestinal mucosal tract and selectively inhibits
the enzyme pyrimidine phosphoribosyl transferase, which
converts 5-FU to 5-ﬂourouridine 50-monophosphate
(FUMP), and consequently attenuates gastrointestinal
toxicity [14]. Phase II trials have demonstrated that S-1,
as a single agent, has superior antitumor effect for the
treatment of gastric, colorectal, head and neck, breast,
non-small cell lung, and pancreatic cancers, especially
gastrointestinal tumors which often highly express DPD
[15–18]. However, to our knowledge, there has been no
study addressing the effect of S-1 on MPM.
The aim of this study was to investigate the preclinical
therapeutic ability of S-1 against MPM in relation to the
expression of DPD and/or thymidine phosphorylase (TP).
By using an orthotopic implantation model, we examined
whether S-1 could reduce the production of thoracic tumors
and pleural effusion produced by human MPM cells.
Treatment with S-1 signiﬁcantly suppressed the progres-
sion of MPM cells, particularly with both DPD and TP
expressions, and prolonged survival of MPM-bearing
SCID mice.
Materials and methods
Cell cultures
The human MPM cell line Y-MESO-14 was established as
described previously [19]. The human MPM cell lines
NCI-H290 and MSTO-211H cells were purchased from
American Type Culture Collection (Manassas, VA). These
tumor cell lines were maintained in RPMI1640 (Nissui
Pharmaceutical Co., Tokyo, Japan) supplemented with
10% heat-inactivated fetal bovine serum (FBS; GIBCO,
Grand Island, NY), penicillin (100 U/ml), and streptomy-
cin (50 lg/ml). Human umbilical vein endothelial cells
(HUVEC) were maintained in EBM-2 medium with growth
supplement (Lonza, Walkersville, MD) and used for
in vitro experiments at passages 2–4. All cell lines
were incubated at 37C in a humidiﬁed atmosphere of
5% CO2.
Reagents
5-FU was purchased from Wako Pure Chemical Industries
Ltd. (Osaka, Japan). S-1, CDHP, and hydroxypropyl
methylcellulose (HPMC) were provided by Taiho Phar-
maceutical Co., Ltd. (Tokyo, Japan). For in vitro treatment,
5-FU or mixture of 5-FU/CDHP (in a molar ratio of 1:0.4)
was dissolved in DMSO before use. The doses of drugs
were expressed as the doses of 5-FU. For in vivo treatment,
S-1 was dissolved in 0.5% HPMC solution. The doses of
S-1 were expressed as the doses of FT, since FT is the
active component.
In vitro cell proliferation assay
Cell proliferation was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium (MTT) dye
reduction method [20]. Brieﬂy, the tumor cells (2 9 10
3/
well) that had been plated in triplicate in 96-well plates
were incubated in RPMI1640 containing 10% FBS for 24 h
at 37C. Next, the cells were incubated for 72 h in the
presence or absence of various concentrations of 5-FU or
5-FU plus CDHP. Then, 50 ll of stock MTT solution
(2 mg/ml; Sigma–Aldrich, St. Louis, MO) was added to
each well and cells then were incubated for 2 h. The media
containing the MTT solution were removed, and the dark
blue crystals were dissolved by adding 100 ll of DMSO.
Absorbance was measured with a microplate reader
(Dainippon Seiyaku, Tokyo, Japan) at test and reference
wavelengths of 550 and 630 nm, respectively. The IC50
values resulting from 50% inhibition of cell growth were
calculated.
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123Western blotting for determination of DPD
and TP protein level
The whole cell extracts were prepared with Ripa lysis
buffer (Thermo Fisher Scientiﬁc Inc., Rockford, IL), and
protein concentrations were measured using Bradford’s
method. Twenty lg of total cell extract protein were
electrophoresed on 4–10% NuPAGE
 Bis–Tris Mini gels
(at 200 Voltage for 40 min). Then, proteins were electro-
blotted onto iBlot
TM gel Tranfer Stacker polyvinylidene
diﬂuoride (PVDF) membrane (Invitrogen, Carlsbad, CA)
according to manufacturer’s instruction. The PVDF mem-
branes were then blocked with a 0.2% non-fat milk/Tris-
Buffer Saline Tween 20 solution in blot holders (SNAP
i.d
TM Protein Detection System, Millipore, Billerica, MA).
Transferred membranes were incubated with mouse
monoclonal antibody against human DPD (1:150 dilution,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or with
mouse monoclonal antibody against human TP as descri-
bed previously [21] or with anti-b-actin antibody (1:600
dilution; Sigma–Aldrich, St. Louis, MO) at room temper-
ature for 10 min, followed by incubation for 10 min at
room temperature with horseradish peroxidase–conjugated
goat antimouse IgG (1:3,000 dilution; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA). Protein–antibody
conjugates were then developed using enhanced chemilu-
minescent substrate (Thermo Fisher Scientiﬁc Inc.,
Rockford, IL). Finally, the immunoreactive bands were
read under Luminescent Image Analyzer (LAS-4000 mini;
Fuji Film, Tokyo, Japan).
Animals
Male SCID mice, 6–7 weeks old, were obtained from
CLEA Japan (Osaka, Japan) and maintained under speciﬁc
pathogen-free conditions throughout this study. All exper-
iments were performed in accordance with the guidelines
of University of Tokushima, Committee on Animal Care
and Use.
Orthotopic implantation model
The human MPM cells were harvested and washed with
Ca
2?- and Mg
2?-free phosphate-buffered saline (PBS;
Nissui Pharmaceutical Co., Tokyo, Japan). Cell viability
was determined by a trypan blue exclusion test, and
only single cell suspensions of[90% viability were used.
Y-MESO-14 (1 9 10
6 cells/100 ll PBS/mouse), NCI-
H290 (3 9 10
5 cells/100 ll PBS/mouse) or MSTO-211H
cells (1 9 10
6 cells/100 ll PBS/mouse) were injected into
the thoracic cavity of SCID mice on day 0 [19, 22, 23].
Before S-1 administration, the mice were randomly divided
into control and treatment groups. Oral administration of
S-1 (5 or 10 mg/kg) or vehicle was given once daily with
various treatment schedules. The general condition of
tumor-bearing mice was checked every day and their body
weights were measured weekly. On day 21, the mice were
killed and the thoracic tumors were weighed. The pleural
effusion was harvested using a 1-ml syringe, and its vol-
ume was measured.
Immunohistochemical staining for DPD and TP
Mouse tumor tissue samples were ﬁxed in 10% formalin
solution and embedded in parafﬁn. Deparafﬁnized 4-lm
sections of tissue were heated in citrate buffer (pH 6.0) for
10 min followed by incubation with 0.3% H2O2 for
blocking of endogenous peroxidase. The sections were then
incubated with primary mouse monoclonal antibody
against human DPD (1:100 dilution, Santa Cruz) or rabbit
polyclonal antibody against human TP [21]a t4 C over-
night. Then, horseradish peroxidase–conjugated species-
speciﬁc secondary antibodies (Amersham Biosciences,
Buckinghamshire, UK) were applied for 60 min at room
temperature. Immune complexes were visualized with
DAB substrate kit (Vector Laboratories Inc., Burlingame,
CA). Negative control was carried out by omitting primary
antibody.
Statistical analysis
The signiﬁcance of differences in cell proliferation assay
was analyzed by the Student’s t test (two-tailed). The in
vivo data were analyzed using Wilcoxon test and Holm’s
procedure (Tukey test) test, when applicable. The proba-
bility of survival was calculated with the Kaplan–Meier
method, and differences between curves were evaluated
with the log-rank test. The P-values less than 0.05 were
considered signiﬁcant in all experiments.
Results
CDHP enhanced the antitumor activity of 5-FU in vitro
We examined whether CDHP could enhance the sensitivity
of the MPM cell lines to 5-FU. The cells were treated with
5-FU or 5-FU plus CDHP in various concentrations for
72 h. Cell proliferation was determined by MTT assay as
described in Materials and Methods. Means of IC50 values
from 3 to 5 independent experiments were compared. The
IC50 values of 5-FU in the presence of CDHP were sig-
niﬁcantly lower than those of 5-FU alone in treatment of
Y-MESO-14 cells (0.22 lg/ml; 95% conﬁdence interval
[CI]: 0.18–0.26 versus 0.92 lg/ml; 95% CI: 0.75–1.1
lg/ml; P\0.0001) and NCI-H290 cells (0.41 lg/ml;
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12395% CI: 0.34–0.48 versus 0.59 lg/ml; 95% CI: 0.50–0.70
lg/ml; P = 0.003). We observed same tendency in MSTO-
211H cells, though the difference was not signiﬁcant
(0.57 lg/ml; 95% CI: 0.44–0.74 versus 0.77 lg/ml; 95%
CI: 0.44–1.1 lg/ml; P = 0.20). These data indicated that
CDHP potentiated the effect of 5-FU in inhibiting the
proliferation of MPM cells.
Expression of DPD and TP in mesothelioma cell lines
DPD is the rate-limiting enzyme in 5-FU breakdown. One
of the most important compounds of S-1 is CDHP, which
has ability to inhibit DPD activity. Several lines of evi-
dence suggest that the intracellular expression of DPD is
closely involved with superior antitumor activity of S-1
[13, 17]. On the other hand, TP has also been reported to
mediate the sensitivity of cancer cells to 5-FU [24–26].
Thus, we examined the expression level of DPD and TP
protein in MPM cell lines. All the three cell lines strongly
expressed DPD protein (Fig. 1a, top), which might beneﬁt
CDHP-mediated modulation of 5-FU-based treatment
observed in results of proliferation assay. The expression
level of TP was remarkable in Y-MESO-14 cells, but
undetectable in the other two MPM cell lines (Fig. 1a,
middle). Among the three MPM cell lines, Y-MESO-14
cells, which expressed both DPD and TP, appeared the
most sensitive to 5-FU in the presence of CDHP (the IC50
value of 5-FU plus CDHP was 4 times lower than that of
5-FU alone). These results suggested that the co-expression
of DPD and TP might enhance the therapeutic effect of
5-FU combined with CDHP on human MPM cells.
Determination of the expression of DPD and TP
in orthotopically implanted MPM cells in SCID mice
The human MPM cells, Y-MESO-14, NCI-H290 or
MSTO-211H, were orthotopically inoculated into the tho-
racic cavity of SCID mice. These MPM cells were able to
produce thoracic tumors and bloody pleural effusion. To
conﬁrm the expression of DPD and TP in orthotopically
implanted MPM cells in SCID mice, immunohistochemical
staining for human DPD and human TP was performed.
Consistent with the result of Western blotting, thoracic
tumors produced by MPM cells expressed comparable
DPD levels among three MPM cells, whereas TP expres-
sion in tumor from Y-MESO-14 cells was clearly higher
than that in tumors from NCI-H290 or MSTO-211H cells
(Fig. 1b).
Fig. 1 Expression of DPD and
TP protein in human MPM
cells. Cell lysates were
harvested and subjected in
duplicate to Western blotting
analysis for DPD and TP.
Images are representatives of
three independent experiments
with similar results (a).
Thoracic tumors produced by
human MPM cells in mice were
harvested and subjected to
immunohistochemical staining
for DPD and TP protein. Images
are representatives of two
separate experiments with
similar results (9200) (b)
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tumors and pleural effusion by Y-MESO-14 cells
in orthotopic implantation model
To assess the therapeutic effects of S-1, beginning 7 days
after MPM cell inoculation, the mice were treated with S-1
(10 mg/kg), or vehicle (HPMC) as a control, daily for
2 weeks, since we have already conﬁrmed that these MPM
cells produced thoracic tumors larger than 1 mm in diam-
eter at this time [19]. Treatment with S-1 signiﬁcantly
reduced the production of thoracic tumors and pleural
effusion in Y-MESO-14 cell-bearing mice compared with
vehicle treatment group (Figs. 2a, b, 3). In NCI-H290 cell-
bearing mice, treatment with S-1 tended to reduce tumor
weight and pleural effusion volume in the thoracic cavity,
but not signiﬁcant (Fig. 2c, d). S-1 had no obvious effect in
inhibiting tumor growth in MSTO-211H cell-bearing mice
(Fig. 2e, f). These results were consistent with the effect of
5-FU combined with CDHP on the proliferation of MPM
cells in vitro. Thus, we used Y-MESO-14 cells for further
investigation.
We next examined the dose–response relationship of S-1
in Y-MESO-14 cell-bearing mice. Treatment with S-1 from
day 7 to 20 revealed dose-dependent inhibition of tumor
growth of orthotopically implanted Y-MESO-14 cells in
SCID mice (Fig. 4a, b). Particularly, the effect of S-1 at the
dose of 10 mg/kg/day was signiﬁcantly superior compared
with that at the dose of 5 mg/kg/day in inhibiting tumor
(Fig. 4a). On the other hand, S-1 was well tolerated in all set
of experiments, as determined by the absence of weight loss
or other signs of acute or delayed toxicity (data not shown).
Therefore, treatment with S-1 at the dose of 10 mg/kg/day
for 14 days (day 7–20) was chosen for further experiments.
Moreover, we also tested short treatment courses with a
constant daily dose of S-1 (10 mg/kg/day) for 10 days
under two schedules of administration, running from day 7
to 16 and from day 11 to 20. Interestingly, both schedules
signiﬁcantly diminished the weight of thoracic tumors and
volume of pleural effusion produced by Y-MESO-14 cells
(Fig. 5a, b). The schedule from day 11–20 appeared to be
Fig. 2 Therapeutic effect of S-1 on thoracic tumor and pleural
effusion produced by MPM cells in SCID mice. Y-MESO-14, NCI-
H290, and MSTO-211H cells were inoculated into thoracic cavity of
SCID mice on day 0. The mice were daily treated with vehicle or S-1
(10 mg/kg) for 14 days from day 7 to 20, and sacriﬁced on day 21.
Treatment with S-1 signiﬁcantly reduced tumor and pleural effusion
produced by Y-MESO-14 cells (a, b), but not by NCI-H290 cells (c, d),
and MSTO-211H cells (e, f) in mice. Figure 2c and d showed the
representative data of three separate experiments with similar results.
Figure 2e and f showed the representative data of two separate experi-
mentswithsimilarresults.ThePvalueswereobtainedfromWilcoxontest
Fig. 3 Therapeutic effect of S-1 on the progression of Y-MESO-14
tumor in SCID mice. Y-MESO-14 cells developed thoracic tumors
(upper left, black arrows) and pleural effusion (lower left, white
arrows) in mice treated with vehicle. Treatment with S-1 signiﬁcantly
decreased the mass of tumors (upper right) and bloody pleural
effusion (lower right)
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123more effective than the schedule from day 7–16, at least in
reducing pleural effusion (P = 0.03) (Fig. 5b). Further-
more, the effect of the schedule for 10 days from day 11–20
was comparable to that of the schedule of 14 days (data not
shown). Hence, two regimens of S-1 (10 mg/kg/day) for
14 days (day 7–20) and 10 days (day 11–20) were prefer-
able for survival experiment.
Treatment with S-1 prolonged the survival
of Y-MESO-14 cell-bearing mice
In the ﬁnal experiment, we evaluated the survival beneﬁt of
S-1 on Y-MESO-14 cell-bearing mice. After tumor cell
inoculation, the mice were treated with S-1 at the dose of
10 mg/kg for 10 days (day 11–20) or 14 days (day 7–20)
or vehicle. Interestingly, S-1 given by both treatment
schedules signiﬁcantly prolonged the survival of mice
compared with vehicle treatment (P = 0.02 and 0.02)
(Fig. 6). The median survival times were 31, 42, and
42 days in vehicle, 10-day and 14-day S-1 treatment
groups, respectively.
Discussion
The management of MPM is still challenging due to lack of
sufﬁcient treatment modalities. Recently, pemetrexed in
combination with cisplatin has been approved as the ﬁrst-
line treatment in advanced stages of MPM. Although
patients who were undergone this regimen have been
reported to have a survival improvement (12.1 vs.
9.3 months) [10, 11], the outcome is still very poor. There-
fore,newtherapeuticstrategiesforthemanagementofMPM
areclearlyurgent.Inthepresentstudy,wedemonstratedthat
S-1 had antitumor effect on human MPM cells and that it
induced survival beneﬁt in the orthotopic implantation
model of human MPM. These ﬁndings strongly indicated
that S-1 is a useful therapeutic candidate against human
MPM.
S-1 is a newly developed oral ﬂuoropyrimidine deriva-
tive, containing CDHP which is an active modulator.
CDHP is a strong inhibitor of 5-FU degradation by DPD in
tumor cells, leading to enhance the antitumor activity of
5-FU, especially against tumor cells expressing high level
of DPD [27]. Several lines of evidence have indicated the
inverse correlation between DPD expression in tumor cells
and response to 5-FU-based treatment [17]. In the present
study, we demonstrated that DPD was expressed by three
human MPM cell lines, Y-MESO-14, NCI-H290 and
Fig. 4 The dose–response study of S-1 given for treatment of
Y-MESO-14 cells implanted in SCID mice. Y-MESO-14 cells were
inoculated into thoracic cavity of SCID mice on day 0. The Y-MESO-
14 cell-inoculated mice were daily treated with vehicle or with
various doses of S-1 from day 7 to 20 and sacriﬁced on day 21.
Treatment with S-1 was signiﬁcantly effective to reduce tumor (a),
and pleural effusion (b), in a dose dependent manner. The P values
were obtained from Holm’s procedure (non-parametric Tukey test)
Fig. 5 Effect of various schedules of S-1 treatment on thoracic tumor
and pleural effusion produced by Y-MESO-14 cells in SCID mice.
Y-MESO-14 cells were inoculated into thoracic cavity of SCID mice
on day 0. The mice were treated with vehicle or S-1 (10 mg/kg) for
10 days under two schedules from day 7–16 and from day 11–20.
Both these two treatment schedules resulted in signiﬁcant reduction of
tumor (a), and pleural effusion (b). The schedule from day 11–20
appeared to be more effective than the schedule from day 7–16 in
reducing pleural effusion. The P values were obtained from Holm’s
procedure (non-parametric Tukey test)
Fig. 6 The effect of S-1 administration on the survival of MPM cell-
bearing SCID mice. Y-MESO-14 cell-bearing mice were treated with
vehicle or with S-1 (10 mg/kg, daily) for 10 days (day 11–20) or
14 days (day 7–20). There were signiﬁcant differences between 10-
day treatment and vehicle groups (P = 0.02) and between 14-day
treatment and vehicle groups (P = 0.02). The median survival times
were 31, 42 and 42 days in vehicle, 10-day and 14-day treatment
groups, respectively. The probability of survival was calculated with
the Kaplan–Meier method, and differences between curves were
evaluated with the log-rank test
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123MSTO-211H cells, and that CDHP enhanced the in vitro
antitumor activity of 5-FU in treatment of these MPM
cells. By contrast, there was no enhancement of response to
5-FU by CDHP addition in human MPM cell lines with low
expression of DPD (data not shown). Although DPD has
been considered as an important predictive marker for S-1
efﬁcacy in various cancers such as colon, gastric, lung
cancers, and hepatocellular carcinoma [28, 29], to our
knowledge, this is the ﬁrst report that human MPM cells
which expressed high level of DPD were more sensitive to
CDHP-modiﬁed 5-FU treatment than to 5-FU alone. TP
has also been reported to mediate the sensitivity of cancer
cells to 5-FU. Schwartz et al. showed that the transfection
of TP into human colon cancer cells, HT-29, increased the
sensitivity to 5-FU [26]. The anabolic conversion of 5-FU
into its active metabolites, such as FUTP or 5-ﬂuoro-20-
deoxyuridine-50-monophosphate (FdUMP), is essential
for its action. TP catalyzes the conversion of 5-FU into
20-deoxy-5-ﬂuorouridine, which is converted directly to
FdUMP by thymidine kinase. In this study, we found that
Y-MESO-14 cells which co-express DPD and TP were
more sensitive to in vitro treatment with 5-FU plus CDHP
and in vivo treatment with S-1 than the other two cell lines
expressing only DPD but not TP (Figs. 1, 2). These ﬁnd-
ings indicated that the co-expression of DPD and TP might
enhance the therapeutic efﬁcacy of S-1 in human MPM
cells.
Previously, we have established a novel orthotopic
MPM model by implanting human MPM cells in the tho-
racic cavity of SCID mice [22]. The inoculated MPM cells
were able to grow and subsequently produce thoracic
tumors and bloody pleural effusion inside the thoracic
cavity of mice. Several weeks after tumor cell inoculation,
MPM cell-bearing mice would die of tumor progression,
illustrating human patient-like features of MPM. This
model was applicable to evaluate the therapeutic effect of
anticancer drugs [19, 22, 23]. In the present study, by using
this model, we evaluated the preclinical therapeutic efﬁ-
cacy of S-1 against human MPM cells. As expected,
treatment with S-1 (10 mg/kg) for 14 days (day 7–20)
remarkably inhibited the progression of Y-MESO-14 cells,
which co-expressed DPD and TP, in mouse thoracic cavi-
ties by reducing thoracic tumor formation and bloody
pleural effusion (Figs. 2a, b, 3). Moreover, the same
schedule of S-1 treatment signiﬁcantly prolonged the sur-
vival of Y-MESO-14 cell-bearing mice (Fig. 6). Clinically,
as patients with MPM are often diagnosed at their
advanced stages, most of such patients cannot receive
sufﬁcient treatment. To investigate whether S-1 could be
effective in clinical relevant settings, we delayed the start
of treatment and curtailed the duration. Importantly, the
delayed and curtailed administration of S-1 (10 mg/kg) for
10 days (day 11–20) also signiﬁcantly inhibited the tumor
progression (Fig. 5) and prolonged the survival of
Y-MESO-14 cell-bearing mice (Fig. 6). These results
suggested that S-1 might be effective against human MPM
even in clinical relevant settings.
In conclusion, we have investigated the therapeutic
efﬁcacy of S-1 against human MPM cells. S-1 had prom-
ising antitumor effect on human MPM cells with both DPD
and TP expressions and prolonged the survival of human
MPM cell-bearing mice. These ﬁndings suggest that S-1
may be a useful therapeutic agent for human MPM.
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